Rep. John Moolenaar (R-Mich.) wants the Pentagon to expand its naughty list. In a letter sent to the U.S. Department of Defense this month, Moolenaar, who chairs the House Select Committee on China, asked the department to add 58 Chinese schools and 62 technology labs to a list tied to U.S. research funding restrictions, Reuters reported on Friday.

What the 1286 List Actually Does

The list is known as the 1286 list, and it matters because of who it touches. Entities that work with Chinese universities on the list can see their research funding affected. The Defense Department is barred from providing research funding to such entities, and it describes collaboration with listed institutions as a compliance risk that could put U.S. federal funding at risk.

Several of the institutions Moolenaar wants added focus on semiconductors, artificial intelligence and quantum computing, according to the letter. In other words, the exact fields where the U.S. and China are racing hardest.

The department did not immediately respond to MarketDash's request for comment.

This is not the first time the list has been in the news. In August, the department said it would investigate 30 U.S. schools over possible collaboration with Chinese institutions on the list.

Tsinghua and the CEO Connection

Moolenaar also requested the inclusion of Tsinghua University, a prominent Chinese institution that has educated members of the country's business and political elite.

Here is where it gets interesting for American investors. Some U.S. business leaders, including the chief executives of NVIDIA Corporation (NVDA), Apple Inc. (AAPL) and Advanced Micro Devices Inc. (AMD), serve on the advisory board of Tsinghua's business school. The board is intended to foster ties between U.S. and Chinese companies, Reuters reported.

So the same universities that Washington wants to flag as a funding risk are also places where some of the biggest names in American tech keep a seat at the table. That tension is not new, but it keeps showing up.

Broader Congressional Scrutiny of China Ties

Earlier this year, in June, lawmakers sought information from Merck & Co. Inc. (MRK) and AbbVie Inc. (ABBV) about clinical trials in China, including data protection and due diligence at research sites. The letters cited potential security and ethical risks but stated there was no evidence that either company had engaged in illegal activity or wrongdoing.

Separately this week, a House panel raised national-security concerns about Webull Corporation (BULL), citing alleged links between its ownership, technology infrastructure and China.

The pattern is clear: Congress is increasingly treating China exposure as something that needs to be documented, disclosed and, in some cases, restricted. For companies with deep ties to Chinese institutions, that means more questions, more paperwork and more headlines.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by MarketDash editors.